Impact of targeting the platelet-activating factor and its receptor in cancer treatment

Abstract The lipid mediator platelet-activating factor (PAF) and its receptor (PAFR) signaling play critical roles in a wide range of physiological and pathophysiological conditions, including cancer growth and metastasis. The ability of PAFR to interact with other oncogenic signaling cascades makes...

Full description

Saved in:
Bibliographic Details
Main Authors: Kimya Qaderi, Arvin Shahmoradi, Anita Thyagarajan, Ravi P. Sahu
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Military Medical Research
Subjects:
Online Access:https://doi.org/10.1186/s40779-025-00597-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850030076763045888
author Kimya Qaderi
Arvin Shahmoradi
Anita Thyagarajan
Ravi P. Sahu
author_facet Kimya Qaderi
Arvin Shahmoradi
Anita Thyagarajan
Ravi P. Sahu
author_sort Kimya Qaderi
collection DOAJ
description Abstract The lipid mediator platelet-activating factor (PAF) and its receptor (PAFR) signaling play critical roles in a wide range of physiological and pathophysiological conditions, including cancer growth and metastasis. The ability of PAFR to interact with other oncogenic signaling cascades makes it a promising target for cancer treatment. Moreover, numerous natural and synthetic compounds, characterized by diverse pharmacological activities such as anti-inflammatory and anti-tumor effects, have been explored for their potential as PAF and PAFR antagonists. In this review, we provide comprehensive evidence regarding the PAF/PAFR signaling pathway, highlighting the effectiveness of various classes of PAF and PAFR inhibitors and antagonists across multiple cancer models. Notably, the synergistic effects of PAF and PAFR antagonists in enhancing the efficacy of chemotherapy and radiation therapy in several experimental cancer models are also discussed. Overall, the synthesis of literature review indicates that targeting the PAF/PAFR axis represents a promising approach for cancer treatment and also exerts synergy with chemotherapy and radiation therapy.
format Article
id doaj-art-0bc279c232164db5905a50975587efed
institution DOAJ
issn 2054-9369
language English
publishDate 2025-03-01
publisher BMC
record_format Article
series Military Medical Research
spelling doaj-art-0bc279c232164db5905a50975587efed2025-08-20T02:59:19ZengBMCMilitary Medical Research2054-93692025-03-0112112710.1186/s40779-025-00597-0Impact of targeting the platelet-activating factor and its receptor in cancer treatmentKimya Qaderi0Arvin Shahmoradi1Anita Thyagarajan2Ravi P. Sahu3Department of Molecular and Cell Biology, College of Life Sciences, University of LeicesterDepartment of Laboratory Medicine, Faculty of Paramedical, Kurdistan University of Medical SciencesDepartment of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State UniversityDepartment of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State UniversityAbstract The lipid mediator platelet-activating factor (PAF) and its receptor (PAFR) signaling play critical roles in a wide range of physiological and pathophysiological conditions, including cancer growth and metastasis. The ability of PAFR to interact with other oncogenic signaling cascades makes it a promising target for cancer treatment. Moreover, numerous natural and synthetic compounds, characterized by diverse pharmacological activities such as anti-inflammatory and anti-tumor effects, have been explored for their potential as PAF and PAFR antagonists. In this review, we provide comprehensive evidence regarding the PAF/PAFR signaling pathway, highlighting the effectiveness of various classes of PAF and PAFR inhibitors and antagonists across multiple cancer models. Notably, the synergistic effects of PAF and PAFR antagonists in enhancing the efficacy of chemotherapy and radiation therapy in several experimental cancer models are also discussed. Overall, the synthesis of literature review indicates that targeting the PAF/PAFR axis represents a promising approach for cancer treatment and also exerts synergy with chemotherapy and radiation therapy.https://doi.org/10.1186/s40779-025-00597-0Platelet-activating factor (PAF)Platelet-activating factor-receptor (PAFR)AntagonistsInhibitorsCancerCell signaling pathways
spellingShingle Kimya Qaderi
Arvin Shahmoradi
Anita Thyagarajan
Ravi P. Sahu
Impact of targeting the platelet-activating factor and its receptor in cancer treatment
Military Medical Research
Platelet-activating factor (PAF)
Platelet-activating factor-receptor (PAFR)
Antagonists
Inhibitors
Cancer
Cell signaling pathways
title Impact of targeting the platelet-activating factor and its receptor in cancer treatment
title_full Impact of targeting the platelet-activating factor and its receptor in cancer treatment
title_fullStr Impact of targeting the platelet-activating factor and its receptor in cancer treatment
title_full_unstemmed Impact of targeting the platelet-activating factor and its receptor in cancer treatment
title_short Impact of targeting the platelet-activating factor and its receptor in cancer treatment
title_sort impact of targeting the platelet activating factor and its receptor in cancer treatment
topic Platelet-activating factor (PAF)
Platelet-activating factor-receptor (PAFR)
Antagonists
Inhibitors
Cancer
Cell signaling pathways
url https://doi.org/10.1186/s40779-025-00597-0
work_keys_str_mv AT kimyaqaderi impactoftargetingtheplateletactivatingfactoranditsreceptorincancertreatment
AT arvinshahmoradi impactoftargetingtheplateletactivatingfactoranditsreceptorincancertreatment
AT anitathyagarajan impactoftargetingtheplateletactivatingfactoranditsreceptorincancertreatment
AT ravipsahu impactoftargetingtheplateletactivatingfactoranditsreceptorincancertreatment